United Therapeutics Corporation
UTHR
$515.46
-$12.45-2.36%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 3.15B | 3.17B | 3.18B | 3.13B | 3.08B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 3.15B | 3.17B | 3.18B | 3.13B | 3.08B |
| Cost of Revenue | 437.20M | 425.30M | 384.40M | 356.90M | 339.10M |
| Gross Profit | 2.72B | 2.74B | 2.80B | 2.77B | 2.74B |
| SG&A Expenses | 762.50M | 746.60M | 732.60M | 701.80M | 674.10M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.75B | 1.71B | 1.67B | 1.60B | 1.53B |
| Operating Income | 1.40B | 1.46B | 1.52B | 1.53B | 1.54B |
| Income Before Tax | 1.57B | 1.61B | 1.71B | 1.67B | 1.62B |
| Income Tax Expenses | 262.10M | 321.30M | 379.20M | 394.70M | 374.90M |
| Earnings from Continuing Operations | 1.31K | 1.29K | 1.33K | 1.27K | 1.24K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 1.31B | 1.29B | 1.33B | 1.27B | 1.24B |
| EBIT | 1.40B | 1.46B | 1.52B | 1.53B | 1.54B |
| EBITDA | 1.49B | 1.55B | 1.60B | 1.61B | 1.62B |
| EPS Basic | 30.28 | 29.33 | 30.18 | 28.51 | 27.71 |
| Normalized Basic EPS | 22.66 | 23.40 | 23.91 | 23.79 | 23.93 |
| EPS Diluted | 27.95 | 27.09 | 27.90 | 26.38 | 25.61 |
| Normalized Diluted EPS | 20.92 | 21.63 | 22.12 | 22.02 | 22.12 |
| Average Basic Shares Outstanding | 173.20M | 175.70M | 177.10M | 178.50M | 179.30M |
| Average Diluted Shares Outstanding | 187.60M | 190.10M | 191.50M | 192.90M | 194.00M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |